Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries

Eder, S. et al. (2019) Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. Diabetes and Vascular Disease Research, 16(1), pp. 47-56. (doi:10.1177/1479164118795559) (PMID:30238781)

[img]
Preview
Text
167874.pdf - Accepted Version

612kB

Abstract

Background: The number of patients with type 2 diabetes mellitus and diabetes mellitus–associated chronic kidney disease varies considerably between countries. Next to differences in genetic as well as life style risk factors, varying practices in medical care delivery might cause this diversity. Method: The PROVALID study recruited 4000 patients with type 2 diabetes mellitus at the primary level of healthcare in five European countries (Austria, Hungary, The Netherlands, Poland and Scotland). Baseline data were used to describe patient characteristics and compare the adherence to ADA (American Diabetes Association) and KDIGO (Kidney Disease: Improving Global Outcomes) guidelines with respect to metabolic and blood pressure control, use of renin–angiotensin system–blocking agents, statins and acetylsalicylic acid between the countries. Results: About 34.8% of the population had evidence of diabetes mellitus–associated chronic kidney disease. The median HbA1c level of the cohort was 6.8% (ranging from 6.5 in Poland to 7.0% in Scotland). Mean blood pressure was 136/79 (±17/10) and significantly higher in subjects with elevated albuminuria. These individuals also were more often treated with renin–angiotensin system–blocking agents (74.1% vs 84.6%), whereas the use of statins was driven by cardiovascular comorbidity. Acetylsalicylic acid was used in only 28.9% subjects. Despite similar cardiovascular comorbidities and renal function, the use of renin–angiotensin system–blocking agents varied significantly between the countries from 66.7% to 87.4%. An even higher variability was observed for patients >40 years of age using statins (39.8%–82.7%) and administration of acetylsalicylic acid in patients older than 50 years (5.2%–43.8%). Conclusion: Our study shows that medical practice in type 2 diabetes mellitus patients with and without renal disease is different in European countries. Longitudinal follow-up will reveal if this diversity affects clinical endpoints.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mark, Dr Patrick
Authors: Eder, S., Leierer, J., Kerschbaum, J., Rosivall, L., Wiecek, A., de Zeeuw, D., Mark, P. B., Heinze, G., Rossing, P., Heerspink, H. L., and Mayer, G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Diabetes and Vascular Disease Research
Publisher:SAGE Publications
ISSN:1479-1641
ISSN (Online):1752-8984
Published Online:21 September 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Diabetes and Vascular Disease Research 16(1): 47-56
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
508901sysKID (PROVALID Study)Alan JardineEuropean Commission (EC)N/ARI CARDIOVASCULAR & MEDICAL SCIENCES